BriaCell Therapeutics (CVE:BCT) Given New C$15.00 Price Target at HC Wainwright

BriaCell Therapeutics (CVE:BCT) had its target price decreased by research analysts at HC Wainwright from C$18.00 to C$15.00 in a research report issued on Thursday, BayStreet.CA reports. HC Wainwright’s price target points to a potential upside of 41.51% from the company’s current price.

BriaCell Therapeutics Stock Down 3.8 %

BCT stock traded down C$0.42 during trading hours on Thursday, reaching C$10.60. 3,402 shares of the stock were exchanged, compared to its average volume of 12,671. The firm’s 50-day moving average is C$10.60 and its 200-day moving average is C$10.60. The company has a market cap of C$168.68 million and a price-to-earnings ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. BriaCell Therapeutics has a 12 month low of C$3.50 and a 12 month high of C$15.75.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.